Aller au contenu

514 606-3350

info@cliniqueomicron.ca​

FR / EN
Logo - Clinique Omicron
Make an appointment
Endocrinology - Thyroid pathology

Graves' disease (Graves)

Graves' disease is an autoimmune disorder and the leading cause of hyperthyroidism in Canada. It occurs when the immune system produces antibodies directed against TSH (thyroid-stimulating hormone) receptors, causing excessive and continuous stimulation of the thyroid gland. The thyroid then secretes abnormal quantities of the hormones T3 and T4, accelerating the body's overall metabolism. The disease affects around seven to eight women for every man, and most often appears between the ages of 20 and 50, although no age group is spared. In addition to hyperthyroidism, it may be accompanied by exophthalmos (protruding eyeballs) and, more rarely, pretibial dermopathy. Early diagnosis and appropriate management are essential to prevent the cardiovascular and bone complications associated with a prolonged excess of thyroid hormones.
Emergency: thyrotoxic crisis

Thyrotoxic crisis (or thyroid storm) is a rare but potentially fatal complication of untreated or decompensated Graves' disease. It manifests as high fever, severe tachycardia, extreme agitation, confusion and vomiting. This situation constitutes an absolute medical emergency.

Call 911 immediately.

Autoimmune mechanism

In Graves' disease, the immune system produces thyroid stimulating immunoglobulins (TSI), also known as TSH receptor antibodies (TRAK). These antibodies bind to thyroid follicular receptors and activate them autonomously, independently of the usual pituitary signals. The thyroid, constantly stimulated, increases in volume (goiter) and excessively secretes thyroid hormones. This immune dysfunction is often triggered or exacerbated by stress, infection, pregnancy or excessive iodine intake.

ℹ️ Graves' disease is distinguished from other causes of hyperthyroidism (toxic nodule, thyroiditis) by the presence of TRAK antibodies, characteristic ophthalmopathy and diffuse goiter. TRAK assay confirms the diagnosis.

Symptoms and clinical manifestations

Manifestations result from excess circulating thyroid hormones and, in some cases, specific autoimmune involvement of eye and skin tissues.

System Common manifestations
General and metabolism Weight loss despite preserved or increased appetite, heat intolerance, excessive sweating, fatigue
Cardiovascular Palpitations, resting tachycardia, systolic hypertension, risk of atrial fibrillation
Neuropsychiatric Nervousness, irritability, insomnia, fine hand tremors, emotional lability
Muscular and bone Proximal muscle weakness, amyotrophy, accelerated bone remodelling (risk of osteoporosis)
Ocular (Graves' ophthalmopathy) Exophthalmos, palpebral retraction, diplopia, lacrimation, photophobia, foreign body sensation
Thyroid Diffuse, soft, painless goiter, sometimes vascular murmur on auscultation
Skin and appendages Hot, clammy skin, fine, brittle hair, onycholysis, pretibial myxedema (rare).
Menstrual cycle Menstrual irregularities, oligomenorrhea, impact on fertility

Diagnosis

The diagnosis of Graves' disease is based on a combination of clinical, biological and, in some cases, thyroid imaging data.

  • Measurement of TSH (collapsed), free T4 and free T3 (elevated)
  • Determination of TRAK antibodies (anti-TSH receptors): a specific marker for Graves' disease
  • Anti-TPO and anti-thyroglobulin antibody tests (frequently positive)
  • Thyroid ultrasound: diffuse goiter, hypervascularization on color Doppler
  • Thyroid scintigraphy if diagnostic doubt: diffuse, homogeneous hyperfixation
  • Lipid profile, blood glucose, CBC (systemic effects of hyperthyroidism)
  • ECG in case of palpitations or tachycardia
  • Ophthalmological evaluation in the presence of ocular signs

Treatment options

Three main treatment modalities are available. The choice depends on the patient's age, the severity of the hyperthyroidism, the presence of ophthalmopathy, the desire for pregnancy and the individual's informed preferences.

Treatment Principle Remarks
Synthetic antithyroid drugs (ATS) Methimazole (Tapazole) or propylthiouracil (PTU): reduce hormone production First-line treatment; usually lasts 12 to 18 months; risk of relapse on discontinuation in 40 to 60 % of cases
Radioactive iodine (iodine-131) Selective destruction of hyperfunctional thyroid tissue by internal irradiation Definitive treatment; often leads to permanent hypothyroidism requiring levothyroxine supplementation; contraindicated in pregnancy and severe active ophthalmopathy
Total thyroidectomy Surgical removal of the thyroid gland under general anesthesia Fast, definitive option; indicated in cases of large goitre, suspected associated neoplasia or contraindication to other treatments; definitive post-operative hypothyroidism
Beta-blockers Propranolol or atenolol: rapid symptomatic control (palpitations, tremors, anxiety) Adjuvant treatment only, with no effect on the autoimmune cause
ℹ️ Graves' ophthalmopathy is treated separately from hyperthyroidism. It may require intravenous corticosteroid therapy, orbital radiotherapy or surgical decompression, depending on severity. Smoking is the main modifiable risk factor for ocular aggravation.

Graves' disease and pregnancy

Graves' disease presents specific challenges in pregnancy. Maternal TRAKs cross the placenta and can induce transient neonatal hyperthyroidism. Propylthiouracil (PTU) is preferred to methimazole in the first trimester, due to its more favorable teratogenic profile. Close monitoring by the general practitioner, endocrinologist and obstetrician is recommended throughout pregnancy and in the post-partum period, when relapse is likely.

Long-term monitoring and development

Biological monitoring (TSH, free T4) is carried out regularly, more frequently at the start of treatment, then at intervals depending on clinical stability. Bone mineral density monitoring is indicated in cases of prolonged hyperthyroidism. After definitive treatment with radioactive iodine or thyroidectomy, levothyroxine substitution (Synthroid) is initiated and adjusted according to the results of the thyroid work-up.

Consult at Clinique Omicron

Clinique Omicron has physicians and specialized nurse practitioners (NPs) trained in the detection and management of thyroid dysfunctions, including Graves' disease. An initial workup, including TSH, free T4 and TRAK antibody assays, can be rapidly prescribed and interpreted at our Quebec outlets. In the event of a confirmed diagnosis, referral to endocrinology is facilitated according to clinical needs. Book an appointment online or by phone at one of Clinique Omicron's points of service on the South Shore and elsewhere in Quebec.

The content of this page is provided for informational purposes only and is not intended to replace the advice of a qualified healthcare professional. Consult a physician for any symptoms, questions or decisions you may have regarding your health.

Omicron Clinic

Need to consult a doctor?

Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.

Insurance receipts. 7j/7. No family doctor required.

Skip to content